Background and objectivesThere is significant interest and potential in the treatment of neuroendocrine tumors via peptide receptor radionuclide therapy (PRRT) using one or both of 90 Y and 177 Lu-labeled peptides. Given the presence of different tumor sizes in patients and differing radionuclide dose delivery properties, the present study aims to use Monte Carlo simulations to estimate S-values to spherical tumors of various sizes with 90 Y and 177 Lu separately and in combination. The goal is to determine ratios of 90 Y to 177 Lu that result in the largest absorbed doses per decay of the radionuclides and the most suitable dose profiles to treat tumors of specific sizes. Material and methodsParticle transfer calculations and simulations were performed using the Monte Carlo GATE simulation software. Spherical tumors of different sizes, ranging from 0.5 to 20 mm in radius, were designed. Activities of 177 Lu and 90 Y, individually and in combination, were homogeneously placed within the total volume of the tumors. We determined the S-values to the tumors, and to the external volume outside of the tumors (cross-dose) which was used to approximate background tissue. The dose profiles were obtained for each of the different tumor sizes, and the uniformity of dose within each tumor was calculated.Results For all tumor sizes, the self-dose and crossdose per decay from 90 Y were higher than that from 177 Lu. We observed that 177 Lu had the most uniform dose distribution within tumors with radii less than 5 mm. For tumors greater than 5 mm in radius, a ratio of 25% 90 Y to 75% 177 Lu resulted in the most uniform doses. When the ratio of 177 Lu to 90 Y was smaller, the uniformity improved more with increasing tumor size. The cross-dose stayed approximately constant for tumors larger than 15 mm for all ratios of 177 Lu to 90 Y. Finally, as the size of the tumor increased, differences in the S-values between different ratios of 177 Lu to 90 Y decreased. ConclusionOur work showed that to achieve a more uniform dose distribution within the tumor, 177 Lu alone is more effective for small tumors. For medium and large tumors, a ratio of 90 Y to 177 Lu with more or less 177 Lu, respectively, is recommended.
Background: 90 Y and 177 Lu are two well-known radionuclides used in radionuclide therapy to treat neuroendocrine tumors. Objective: This current study aims to evaluate, compare and optimize tumor therapy with 90 Y and 177 Lu for different volumes of the tumor using the criterion of self-absorbed dose, cross-absorbed dose, absorbed dose profile, absorbed dose uniformity, and dose-volume histogram (DVH) curve using Gate Monte Carlo simulation code. Material and Methods: In our analytical study, Gate Monte Carlo simulation code has been used to model tumors and simulate particle transport. Spherical tumors were modeled from radius 0.5 to 20 mm. Tumors were uniformly designed from water (soft tissue reagent). The full energy spectrum of each radionuclide of 177 Lu and 90 Y was used in the total volume of tumors with isotropic radiation, homogeneously. Self-absorbed dose, cross-absorbed dose, absorbed dose profile, absorbed dose uniformity, and DVH curve parameters were evaluated. Results: The absorbed dose for 90 Y is higher than 177 Lu in all tumors (p-value <5%). The uniformity of the absorbed dose for 177 Lu is much greater than 90 Y. As the tumor size increases, the DVH graph improves for 90 Y. Conclusion: Based on self-absorbed dose, cross-absorbed dose, absorbed dose uniformity, and DVH diagram, 177 Lu and 90 Y are appropriate for smaller and larger tumors, respectively. Next, we can evaluate the appropriate cocktail of these radionuclides, in terms of the type of composition, for the treatment of tumors with a specific size.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.